Kazakhstan. Foreign Investors in the Pharmaceutical Market in Kazakhstan
In September 2011, ‘Polpharma’, an investor from Poland, became the majority shareholder in Shymkent JSC ‘Khimpharm’ - a plant, which supplies 55% of Kazakhstan's pharmaceutical products. It now operates under the brand ‘Santo’. In 2013, a new ampoule workshop, built as a part of the investment project, will be put into operation. Tablet preparation plants will be completed in the first half of 2014.
The second largest company in terms of production (7%) in Kazakhstan is the ‘Nobel Almaty Pharmaceutical Factory’; its main investor has been the Turkish company ‘Nobel Ilac’ since 2002. The third largest firm in terms of production (5%) is the company ‘Abdi Ibrahim Global Pharm LLP’, whose production facilities are located in the Almaty Province. Previously, it used to be a Kazakh company ‘Global Pharm’. In October 2012, 60% of its shares were acquired by an investor from Turkey, ‘Abdi Ibrahim’. Now, a joint Kazakh-Turkish project worth $60 million is underway; including the construction of a new pharmaceutical plant in Kazakhstan by the end of 2014.
In August 2012, a Russian group of companies ’Pharmstandard’ became a shareholder of LLP ‘Karaganda Pharmaceutical Plant’. In October 2012, a Kazakh-Czech business forum was held. During the course of the event, a contract on the construction of two new pharmaceutical manufacturing facilities in Semipalatinsk and Pavlodar was concluded between the Kazakh company ‘Romat’ and the company ‘Favea Europe’. The new plants should be fully compliant with the international standards (GMP).
The funding of the project will be provided by two companies. The total investment amounts to 37 million euro. According to the plans, both companies will become profitable in the first half of 2014.
Source: Open Dialog Foundation
Leave a Comment